FDA Confirmation of Full Regulatory Transfer

AMR Bio Receives FDA Confirmation of Full Regulatory Transfer

AMR Bio has received formal confirmation from the US Food and Drug Administration (FDA) that the full transfer of its XF-73 regulatory assets is now complete.

Since AMR Bio’s launch announcement in May 2026, the company has secured written confirmation from the FDA that the complete transfer of its XF-73 regulatory assets is now in place, including the Qualified Infectious Disease Product (QIDP) designation and Fast Track (FT) status for XF-73 Nasal under AMR Bio as the new IND sponsor. The transfer of the pre-Investigational New Drug (pIND) application for XF-73 Dermal has also been formally accepted. The confirmations were secured through AMR Bio’s US regulatory agent, Cardinal Health.

Together, these designations unlock Priority Review by the FDA, a rolling submission process, and a five-year extension to market exclusivity upon approval, reflecting the FDA’s recognition of the significant unmet need that XF-73 addresses. QIDP status also applies to XF-73 Dermal, which holds designation for burn wound infections.

With the transfer complete, AMR Bio is now focused on its next regulatory milestone: a Type B or C letter submission to the FDA planned for summer 2026, which will seek formal guidance on the Phase 3 trial design for XF-73 Nasal. In the UK, the MHRA has granted AMR Bio Accelerated Access Status under the Innovative Licensing and Access Pathway (ILAP), further strengthening the company’s route to market on both sides of the Atlantic.

Nigel Brooksby, Executive Chair of AMR Bio, commented:

“Receiving written confirmation from the FDA that our full suite of regulatory designations has transferred to AMR Bio is an important step. The regulatory foundations for XF-73 are firmly in place as we move into the next phase of the programme.”